Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359)

Ophthalmology. 2017 Jan;124(1):e5. doi: 10.1016/j.ophtha.2016.03.052.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bevacizumab*
  • Humans
  • Macular Edema
  • Ranibizumab*
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins

Substances

  • Recombinant Fusion Proteins
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab